Cochrane · systematic review · CD008652

Pharmacotherapy for hyperuricaemia in hypertensive patients

Gois, PHenrique França, Souza, ERegio de Moraes · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library

Hypertension3 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 83.3%Moderate 0 · 0%High 1 · 16.7%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 3 versions

Uric acid‐lowering drug compared to placebo for people with hyperuricaemia

Population: hyperuricaemia in people with hypertension
6 questions
OutcomeEffectEvidenceStatus / GRADE
24‐h ambulatory systolic BP
Uric acid‐lowering drug vs placebo
no estimate extracted3 studies · 229 participantsLow
Downgraded: imprecision, inconsistency
24‐h ambulatory diastolic BP
Uric acid‐lowering drug vs placebo
no estimate extracted3 studies · 229 participantsLow
Downgraded: imprecision, inconsistency
Clinic‐measured systolic BP
Uric acid‐lowering drug vs placebo
no estimate extracted2 studies · 120 participantsLow
Downgraded: imprecision, inconsistency
Clinic‐measured diastolic BP
Uric acid‐lowering drug vs placebo
no estimate extracted2 studies · 120 participantsLow
Downgraded: imprecision, inconsistency
Serum UA
Uric acid‐lowering drug vs placebo
no estimate extracted3 studies · 223 participantsHigh
Adverse events (withdrawals due to side effects)
Uric acid‐lowering drug vs placebo
RR 1.86 [0.43, 8.1]3 studies · 241 participantsLow
Downgraded: imprecision